Maternal and Infant Syphilis Prevention Act
- Bill Number
- S. 2004
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-06-10: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2025-12-05T22:49:22Z
AI-Generated Summary
Purpose
The Maternal and Infant Syphilis Prevention Act (S. 2004) aims to combat the rising rates of syphilis, particularly congenital syphilis (syphilis passed from mother to baby during pregnancy), by requiring federal guidance on best practices for screening and treatment. It focuses on improving prevention and care under public health programs like Medicaid (a joint federal-state program providing health coverage to low-income individuals) and the Children's Health Insurance Program (CHIP, which covers children's health for families above Medicaid eligibility limits). The goal is to reduce health risks to pregnant women and newborns through better testing, education, and access to care.
Key Provisions
- Issuance of Guidance: Within 12 months of enactment, the Secretary of Health and Human Services (HHS) must provide guidance to state agencies administering Medicaid and CHIP, as well as the Indian Health Service (IHS), Indian Tribes, tribal organizations, and Urban Indian organizations. The guidance covers best practices for:
- Expanding access to syphilis screening for pregnant women and infants.
- Educating healthcare providers and pregnant women about syphilis risks and prevention.
- Integrating telehealth (remote healthcare services via technology) for screening, treatment, and multilingual resources, including interpreter support.
- Increasing testing during the third trimester of pregnancy and at delivery.
- Enhancing treatment options for syphilis and congenital syphilis.
- Implementation Tools: States and programs can use waivers (temporary exceptions to program rules) under Section 1115 of the Social Security Act, along with existing authorities in Medicaid (Title XIX) and CHIP (Title XXI), to adopt these practices.
- Report to Congress: Within 2 years of enactment, HHS must submit a public report to key congressional committees (House Energy and Commerce, Senate Health, Education, Labor and Pensions, and Senate Finance) analyzing how the best practices are being implemented.
- Findings Section: The bill includes congressional findings on the syphilis epidemic, noting over 209,000 U.S. cases in 2023 (an 80% increase since 2018), rising congenital cases (over 3,800 in 2023, up 3% from 2022), associated risks like stillbirths, infant deaths, and long-term health issues (e.g., vision/hearing loss, developmental delays), and the potential to prevent nearly 90% of cases with timely prenatal screening.
Significant Changes to Existing Law
This bill does not amend existing laws directly but introduces a new mandate for HHS to issue non-binding guidance on best practices. It builds on current Medicaid and CHIP frameworks by encouraging the use of waivers and existing authorities to standardize and expand syphilis screening and treatment, addressing inconsistencies in state-level requirements (e.g., varying mandates for third-trimester or delivery testing). No new funding is authorized, so implementation relies on existing program resources.
Potential Impacts
- Government Agencies: HHS will need to develop and distribute guidance, potentially increasing administrative workload. State Medicaid and CHIP agencies, along with IHS and tribal programs, may see operational changes to incorporate telehealth and expanded screening, possibly straining budgets without additional federal funds.
- Citizens: Pregnant women and infants, especially in low-income or underserved communities (e.g., tribal populations), could benefit from earlier detection and treatment, reducing risks of miscarriage, stillbirth, infant death, and lifelong disabilities. It promotes equitable access through multilingual and telehealth options, but effectiveness depends on state adoption.
- International Relations: No direct impacts, as the bill focuses on domestic public health programs.
Main Stakeholders Affected
- Federal and State Agencies: HHS (leads guidance and reporting), state Medicaid/CHIP administrators (implement practices).
- Tribal and Urban Indian Entities: IHS, Indian Tribes, tribal organizations, and Urban Indian organizations (receive tailored guidance for their health programs).
- Healthcare Providers: Doctors, nurses, and telehealth specialists (gain education and tools for screening/treatment).
- Vulnerable Populations: Low-income pregnant women, newborns at risk of congenital syphilis, and families in Medicaid/CHIP (primary beneficiaries of improved prevention).
- Congressional Committees: Involved in oversight via the required report.
Notable Legal, Constitutional, or Political Implications
- Legal: The bill leverages existing waiver authorities under the Social Security Act, avoiding the need for major statutory overhauls. Guidance is advisory, not enforceable, which limits legal challenges but may result in uneven state compliance.
- Constitutional: No apparent issues; it aligns with Congress's authority to regulate interstate commerce and public health under the Spending Clause (by conditioning federal funds on best practices).
- Political: Bipartisan introduction (by Senators Heinrich, D-NM, and Wicker, R-MS) signals broad support for maternal and child health. It addresses a public health crisis without partisan controversy, potentially serving as a model for future preventive care initiatives, though implementation success hinges on state-level cooperation and resource allocation.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Recent Actions
- 2025-06-10: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-06-10: Introduced in Senate
Bill Versions
- Maternal and Infant Syphilis Prevention Act — issued 2025-06-10 — PDF (6 pages)